Burzynski Research Institute, Inc. (BZYR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Burzynski Research Institute, Inc. (BZYR) trades at $0.006 with AI Score 42/100 (Grade C). Burzynski Research Institute, Inc. focuses on researching and developing antineoplaston drugs for cancer treatment. Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for BZYR: BZYR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BZYR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BZYR: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Burzynski Research Institute, Inc. (BZYR) Healthcare & Pipeline Overview
Burzynski Research Institute, Inc., founded in 1977, is a biotechnology company focused on researching, developing, and marketing antineoplaston drugs for cancer treatment. Operating in the competitive healthcare sector, the company also provides consulting services and produces medical chemical compounds under the Antineoplastons trade name.
What Is the Investment Thesis for BZYR?
Investing in Burzynski Research Institute, Inc. (BZYR) presents a speculative opportunity due to its focus on antineoplaston drugs, a novel approach to cancer treatment. The company's potential value drivers include successful clinical trials and regulatory approvals for its Antineoplastons. However, the company's negative P/E ratio of -2.55 indicates it is not currently profitable. Key risks include the uncertainty of regulatory approval, competition from established cancer therapies, and the challenges of operating in the OTC market. The company's low beta of 0.28 suggests lower volatility compared to the broader market, but this may also reflect limited trading activity.
Based on FMP financials and quantitative analysis
BZYR Key Highlights
- Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
- Negative P/E ratio of -2.55 reflects the company's current lack of profitability.
- Beta of 0.28 suggests lower volatility compared to the overall market.
- Focus on antineoplaston drugs represents a unique approach to cancer treatment.
- The company's operations include research, development, production, marketing, and consulting services.
Who Are BZYR's Competitors?
BZYR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BETRF BetterLife Pharma Inc. | $0.16 | -7.66% | $25.6M | 45 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.35% | $7.58M | 72 |
| BLRX BioLineRx Ltd. | $2.86 | +0.41% | $12.4M | 69 |
| GBIO Generation Bio Co. | $5.34 | +0.00% | $36.0M | 69 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.16 | +3.48% | $170M | 75 |
| CGEN Compugen Ltd. | $2.34 | -3.31% | $221M | 76 |
| ORTX Orchard Therapeutics plc | $16.70 | +0.30% | $380M | 69 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BZYR's Key Strengths?
- Unique antineoplaston therapies.
- Experienced leadership in cancer research.
- Established brand name (Antineoplastons).
- Dedicated focus on alternative cancer treatments.
What Are BZYR's Weaknesses?
- Limited financial resources.
- Dependence on a single product line.
- Lack of profitability (negative P/E ratio).
- OTC market listing (lower liquidity and visibility).
What Could Drive BZYR Stock Higher?
- Results from ongoing clinical trials of Antineoplastons for various cancer types.
- Potential for strategic partnerships with larger pharmaceutical companies.
- Regulatory submissions for Antineoplastons in new geographic markets.
- Development of new antineoplaston formulations.
- Expansion of consulting services related to antineoplaston therapies.
What Are the Key Risks for BZYR?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established cancer therapies and larger pharmaceutical companies.
- Regulatory hurdles and uncertainty surrounding the approval of Antineoplastons.
- Adverse results from clinical trials of Antineoplastons.
- Limited financial resources and dependence on a single product line.
- OTC market listing and associated risks (low liquidity, limited disclosure).
What Are the Growth Opportunities for BZYR?
- Expansion of Clinical Trials: Burzynski Research Institute has the opportunity to expand its clinical trials to new cancer types and patient populations. Positive results from these trials could lead to increased interest in its Antineoplastons and potential regulatory approvals. The global oncology market is projected to reach $286.6 billion by 2030, providing a substantial market for successful cancer therapies. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Burzynski Research Institute with access to additional funding, expertise, and resources. Collaborations could accelerate the development and commercialization of its Antineoplastons. The pharmaceutical industry is increasingly reliant on partnerships to drive innovation. Timeline: Ongoing.
- Regulatory Approval in New Markets: Obtaining regulatory approval for its Antineoplastons in new geographic markets, such as Europe or Asia, could significantly expand the company's revenue potential. Each region has its own regulatory pathway, requiring specific clinical data and documentation. Timeline: 3-5 years.
- Development of New Antineoplaston Formulations: Developing new formulations of its Antineoplastons, such as oral or injectable versions, could improve patient convenience and compliance. This could also expand the potential applications of the drugs. The market for drug delivery technologies is growing rapidly. Timeline: 2-3 years.
- Increased Consulting Services: Expanding its consulting services related to antineoplaston therapies could generate additional revenue and strengthen the company's relationships with healthcare providers. The demand for specialized consulting services in the healthcare industry is increasing. Timeline: Ongoing.
What Opportunities Does BZYR Have?
- Expansion of clinical trials to new cancer types.
- Strategic partnerships with larger pharmaceutical companies.
- Regulatory approval in new geographic markets.
- Development of new antineoplaston formulations.
What Threats Does BZYR Face?
- Competition from established cancer therapies.
- Regulatory hurdles and uncertainty.
- Potential for adverse clinical trial results.
- Changes in healthcare regulations and reimbursement policies.
What Are BZYR's Competitive Advantages?
- Proprietary Antineoplastons: The company's unique antineoplaston drugs represent a potential competitive advantage.
- Specialized Expertise: The company's expertise in antineoplaston therapies is a valuable asset.
- Established Brand: The Antineoplastons trade name has been in use for several years.
- Intellectual Property: Patents related to antineoplaston formulations and uses.
What Does BZYR Do?
Burzynski Research Institute, Inc., established in 1977 and based in Houston, Texas, is a biotechnology company dedicated to the research and development of antineoplaston drugs for cancer treatment. The company's core focus revolves around its proprietary Antineoplastons, which are medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids. These compounds are produced, marketed, and sold by the company. Since its inception, Burzynski Research Institute has been committed to exploring innovative approaches to cancer therapy. The company's activities encompass a range of services, including research, drug development, manufacturing, marketing, and consulting. Its primary product, Antineoplastons, represents a unique approach to cancer treatment, distinguishing it from conventional therapies. The company's operations are primarily based in the United States, with a focus on serving patients and healthcare providers seeking alternative cancer treatment options. Burzynski Research Institute also provides consulting services related to its antineoplaston therapies.
What Products and Services Does BZYR Offer?
- Researches and develops antineoplaston drugs for cancer treatment.
- Produces medical chemical compounds composed of growth-inhibiting peptides.
- Markets and promotes its Antineoplastons trade name products.
- Sells its Antineoplastons products to patients and healthcare providers.
- Offers consulting services related to antineoplaston therapies.
- Focuses on alternative cancer treatment options.
How Does BZYR Make Money?
- Generates revenue through the sale of Antineoplastons.
- Provides consulting services to healthcare providers and patients.
- Invests in research and development of new antineoplaston therapies.
- Markets and promotes its products through various channels.
What Industry Does BZYR Operate In?
Burzynski Research Institute, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant competition. The company's focus on antineoplaston drugs places it in a niche market segment within the broader cancer therapeutics landscape. Competitors include companies like BETRF (Bio-Path Holdings, Inc.), BIXT (Bioxcel Therapeutics, Inc.), BVAXF (Blue Water Vaccines Inc), CPMV (CMP Pharma, Inc.), and FAMDF (Farmaceuticos Argentinos S.A.), all of which are pursuing different approaches to cancer treatment or related therapies. The biotechnology industry is driven by innovation and is subject to stringent regulatory oversight.
Who Are BZYR's Key Customers?
- Cancer patients seeking alternative treatment options.
- Healthcare providers interested in antineoplaston therapies.
- Research institutions involved in cancer research.
- Patients who have exhausted conventional cancer treatments.
Key Financial Metrics
A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -160.5%, the inverse of the P/E and a quick read on earnings relative to price.
How Burzynski Research Institute, Inc. Is Valued
Relative to its peer group, BZYR's quantitative score of 42/100 is below the peer average of 65/100.
F-Score 2/9Financial Health
Burzynski Research Institute, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BZYR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Burzynski's future, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative nature of their research and therapies.
- The company's focus on personalized medicine aligns well with current healthcare trends, attracting interest from investors and patients alike.
- Recent collaborations or partnerships may enhance their research capabilities and market reach, fostering optimism among investors.
Bear Case
- Concerns over the regulatory landscape for their treatments could create uncertainty, impacting investor confidence.
- Social sentiment has also shown skepticism, with some community discussions questioning the viability of their research methods.
- The competitive landscape in the biotech sector is fierce, and Burzynski may struggle to differentiate itself effectively.
- Recent news cycles have spotlighted challenges in funding and operational execution, raising red flags for potential investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BZYR Latest News
No recent news available for BZYR.
BZYR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BZYR.
Price Targets
Wall Street price target analysis for BZYR.
BZYR MoonshotScore
What does this score mean?
The MoonshotScore rates BZYR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Stanislaw R. Burzynski
Founder and CEO
Stanislaw R. Burzynski is the founder and CEO of Burzynski Research Institute, Inc. He is a physician and scientist who has dedicated his career to researching and developing antineoplaston therapies for cancer. Dr. Burzynski received his medical degree from the Medical University of Lublin in Poland and later moved to the United States to continue his research. He has published numerous scientific papers on antineoplastons and their potential in cancer treatment.
Track Record: Under Dr. Burzynski's leadership, Burzynski Research Institute has developed and marketed Antineoplastons for cancer treatment. He has overseen the company's research and clinical trial programs. He has faced scrutiny and controversy regarding his methods, but has also garnered a dedicated following of patients seeking alternative cancer therapies.
BZYR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Burzynski Research Institute, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and the trading of their stock can be highly speculative. Investing in OTC Other stocks carries significant risks compared to stocks listed on major exchanges like the NYSE or NASDAQ, due to less stringent regulatory oversight and reporting requirements.
- OTC Tier: OTC Other
- Limited Disclosure: OTC Other companies often have minimal financial reporting requirements, making it difficult to assess their financial health.
- Low Liquidity: Trading volume is typically very low, leading to wide bid-ask spreads and potential price volatility.
- Regulatory Scrutiny: OTC stocks are subject to less regulatory oversight than exchange-listed stocks, increasing the risk of fraud or mismanagement.
- Going Concern Risk: Companies in the OTC Other tier may be facing financial difficulties or have a limited operating history.
- Information Asymmetry: Lack of readily available information can create an uneven playing field for investors.
- Verify the company's legal standing and registration.
- Review any available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's products or services and their market potential.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Longevity of Operations: The company has been in operation since 1977.
- Focus on Research and Development: The company is actively involved in research and development of cancer therapies.
- Scientific Publications: The company has published scientific papers on antineoplastons.
- CEO with Medical Background: The CEO, Stanislaw R. Burzynski, is a physician and scientist.
- Dedicated Patient Following: The company has a dedicated following of patients seeking alternative cancer therapies.
What Investors Ask About Burzynski Research Institute, Inc. (BZYR) — Healthcare
What does the AI Score mean for BZYR?
BZYR holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Burzynski Research Institute, Inc. focuses on researching and developing antineoplaston drugs for cancer treatment. The company also produces and markets medical chemical compounds under …
What does Burzynski Research Institute, Inc. do?
Burzynski Research Institute, Inc. is a biotechnology company focused on the research, development, production, and marketing of antineoplaston drugs for cancer treatment. Its primary product, Antineoplastons, represents a unique approach to cancer therapy. The company also provides consulting services related to its antineoplaston therapies.
What do analysts say about BZYR stock?
There is currently no available analyst coverage for Burzynski Research Institute, Inc. (BZYR) due to its listing on the OTC Other market and limited financial information. The company's negative P/E ratio of -2.55 indicates it is not currently profitable. Potential investors should carefully consider the risks associated with investing in OTC stocks, including low liquidity, limited disclosure, and regulatory scrutiny.
What are the main risks for BZYR?
The main risks for Burzynski Research Institute, Inc. (BZYR) include regulatory hurdles and uncertainty surrounding the approval of its Antineoplastons, competition from established cancer therapies and larger pharmaceutical companies, potential for adverse results from clinical trials, limited financial resources, and the risks associated with its OTC market listing. The company's dependence on a single product line also poses a risk. Investors should carefully consider these risks before investing in BZYR.
How does Burzynski Research Institute, Inc. manage patent expiration risks?
As a biotechnology company focused on antineoplaston drugs, Burzynski Research Institute, Inc. must actively manage patent expiration risks to protect its intellectual property and maintain its competitive advantage.
What revenue streams does Burzynski Research Institute, Inc. have in healthcare?
Burzynski Research Institute, Inc.'s primary revenue stream is the sale of its Antineoplastons, which are medical chemical compounds used for cancer treatment. The company also generates revenue from consulting services provided to healthcare providers and patients related to its antineoplaston therapies. The relative contribution of each revenue stream is not publicly disclosed.
What are the key factors to evaluate for BZYR?
Burzynski Research Institute, Inc. (BZYR) holds an AI score of 42/100 (low). Not financial advice.
How frequently does BZYR data refresh on this page?
BZYR's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BZYR's recent stock price performance?
Burzynski Research Institute, Inc. (BZYR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Unique antineoplaston therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information is available for Burzynski Research Institute, Inc. due to its OTC market listing.
- Analyst coverage is not available for the company.
- The company's future prospects are subject to regulatory approval and clinical trial outcomes.